[go: up one dir, main page]

MX2015010740A - Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix). - Google Patents

Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).

Info

Publication number
MX2015010740A
MX2015010740A MX2015010740A MX2015010740A MX2015010740A MX 2015010740 A MX2015010740 A MX 2015010740A MX 2015010740 A MX2015010740 A MX 2015010740A MX 2015010740 A MX2015010740 A MX 2015010740A MX 2015010740 A MX2015010740 A MX 2015010740A
Authority
MX
Mexico
Prior art keywords
caix
carbonic
anhydraine
stratification
cancer treatment
Prior art date
Application number
MX2015010740A
Other languages
English (en)
Other versions
MX363845B (es
Inventor
Olaf Wilhelm
Paul Bevan
Barbara Fall
Pia Klöpfer
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of MX2015010740A publication Critical patent/MX2015010740A/es
Publication of MX363845B publication Critical patent/MX363845B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se relaciona con un compuesto dirigido a la anhidrasa carbónica IX para el uso en el tratamiento del cáncer, donde el uso comprende cuantificar la expresión de CAIX así como la determinación de un puntaje CAIX sobre la base de la expresión de CAIX. La presente invención se relaciona además con un método para diagnosticar, predecir y/o clasificar una enfermedad cancerosa que comprende cuantificar la expresión de CAIX, y la determinación de un puntaje de CAIX.
MX2015010740A 2013-02-22 2014-02-21 Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales. MX363845B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768084P 2013-02-22 2013-02-22
US201361829349P 2013-05-31 2013-05-31
PCT/EP2014/053420 WO2014128258A1 (en) 2013-02-22 2014-02-21 Caix stratification based cancer treatment

Publications (2)

Publication Number Publication Date
MX2015010740A true MX2015010740A (es) 2016-04-11
MX363845B MX363845B (es) 2019-04-05

Family

ID=50179596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010740A MX363845B (es) 2013-02-22 2014-02-21 Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales.

Country Status (17)

Country Link
US (1) US10620208B2 (es)
EP (1) EP2958589B1 (es)
JP (1) JP2016511766A (es)
KR (1) KR102172403B1 (es)
CN (2) CN105377295A (es)
AU (1) AU2014220705C1 (es)
BR (1) BR112015020061A8 (es)
CA (1) CA2901531C (es)
ES (1) ES2703572T3 (es)
HK (1) HK1215195A1 (es)
IL (1) IL240499B (es)
MX (1) MX363845B (es)
NZ (1) NZ712023A (es)
RU (1) RU2663694C2 (es)
SG (1) SG11201506635TA (es)
WO (1) WO2014128258A1 (es)
ZA (1) ZA201505937B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015020061A8 (pt) 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
WO2021052982A1 (en) 2019-09-16 2021-03-25 Bracco Imaging Spa Ca-ix aptamers and diagnostic and therapeutic uses thereof
CN110862457B (zh) * 2019-12-05 2021-09-24 中国人民解放军陆军特色医学中心 能与碳酸酐酶ix特异性结合的骆驼源纳米抗体及其应用
US20230384312A1 (en) * 2020-10-23 2023-11-30 Centre National De La Recherche Scientifique Circulating microvesicles expressing carbonic anhydrase 9 for the prognosis of renal cell carcinoma
EP4562100A2 (en) 2022-07-28 2025-06-04 Bracco Imaging SPA Ca-ix targeting fluorescent probes
EP4562099A1 (en) 2022-07-28 2025-06-04 Bracco Imaging SPA Ca-ix targeting fluorescent probes
EP4676520A1 (en) 2023-03-03 2026-01-14 Arsenal Biosciences, Inc. Systems targeting psma and ca9
CN117659128B (zh) * 2023-11-30 2024-07-02 北京大学第一医院 一种碳酸酐酶ix靶向化合物及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
CA2192678C (en) 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein
CA2347649C (en) 1998-10-23 2012-03-13 Institute Of Virology Mn gene and protein
DK1358318T3 (da) 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
MXPA03010804A (es) * 2001-06-01 2004-11-22 Cornell Res Foundation Inc Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos.
CA2467738A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
WO2003089659A1 (en) * 2002-04-16 2003-10-30 The Regents Of The University Of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
DE10240118A1 (de) 2002-08-30 2004-03-11 Wilex Ag Verfahren zur Identifizierung von Nierenzellkarzinom spezifischen Proteinen und deren Verwendung
KR101130181B1 (ko) * 2003-02-27 2012-03-28 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
EP1673630A4 (en) 2003-10-16 2009-04-29 Inst Virology MN / CA IX AND CANCER PROGNOSIS
AU2005241093B2 (en) * 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
WO2006002889A2 (en) * 2004-07-02 2006-01-12 Wilex Ag Improved adjuvant therapy of g250-expressing tumors
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
US8492520B2 (en) * 2007-11-02 2013-07-23 Wilex Ag Binding epitopes for G250 antibody
JP2011509304A (ja) * 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
JP2013504547A (ja) * 2009-09-15 2013-02-07 ウィレックス・アーゲー 腎臓明細胞癌での骨転移の選択的検出
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
BR112015020061A8 (pt) 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer

Also Published As

Publication number Publication date
JP2016511766A (ja) 2016-04-21
AU2014220705B2 (en) 2018-05-17
CA2901531A1 (en) 2014-08-28
US10620208B2 (en) 2020-04-14
CN105377295A (zh) 2016-03-02
BR112015020061A2 (pt) 2017-07-18
NZ712023A (en) 2019-10-25
IL240499B (en) 2020-02-27
ES2703572T3 (es) 2019-03-11
MX363845B (es) 2019-04-05
SG11201506635TA (en) 2015-09-29
US20160002350A1 (en) 2016-01-07
EP2958589B1 (en) 2018-11-21
WO2014128258A1 (en) 2014-08-28
CA2901531C (en) 2022-03-29
RU2663694C2 (ru) 2018-08-08
BR112015020061A8 (pt) 2018-01-23
KR102172403B1 (ko) 2020-11-02
HK1215195A1 (zh) 2016-08-19
EP2958589A1 (en) 2015-12-30
IL240499A0 (en) 2015-09-24
AU2014220705A1 (en) 2015-09-10
ZA201505937B (en) 2019-10-30
AU2014220705C1 (en) 2018-10-18
KR20150119406A (ko) 2015-10-23
CN110208535A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
NI201200175A (es) Métodos de tratamiento de cáncer de vejiga
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
GT201500249A (es) Terapia de combinación
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
BR112013029787A2 (pt) biomarcadores para câncer de pulmão
UY4236Q (es) Configuración aplicada en zapato
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2017012320A (es) Estandares de antigeno prostatico y sus usos.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
EA201401201A1 (ru) Способ
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
MX2015016305A (es) Biomarcador predictivo para terapia contra el cancer.
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
MX2015015015A (es) Metodo para diagnosticar cancer.

Legal Events

Date Code Title Description
FG Grant or registration